PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells
Authors:
- 1 November 2016
- journal article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 310, 9-19
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerNature Reviews Cancer, 2015
- The history and future of targeting cyclin-dependent kinases in cancer therapyNature Reviews Drug Discovery, 2015
- Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer ResearchPLOS ONE, 2013
- Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic propertiesCell Cycle, 2013
- CDC25A targeting by miR-483-3p decreases CCND–CDK4/6 assembly and contributes to cell cycle arrestCell Death & Differentiation, 2013
- miR‐483‐3p controls proliferation in wounded epithelial cellsThe FASEB Journal, 2011
- Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatinBiochemical Pharmacology, 2010
- MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapyGynecologic Oncology, 2009
- Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compoundsMolecular Cancer Therapeutics, 2008
- The potential of protein kinase C as A target for anticancer treatmentPharmacology & Therapeutics, 1993